Vaccine Technologies Global Market Report 2025

The vaccine technologies market size has grown rapidly in recent years. It will grow from $55.59 billion in 2024 to $61.38 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. Growth during the historical period was supported by increasing cases of infectious diseases, enhanced government funding for vaccine-related research, pandemic outbreaks, heightened public awareness of vaccines' advantages, and the broadening of immunization initiatives.

The vaccine technologies market size is expected to see rapid growth in the next few years. It will grow to $90.7 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. This future growth will be driven by the rising demand for mRNA-based vaccines, increased investments in personalized vaccine development, heightened emphasis on cancer immunization, a growing burden of chronic illnesses, and improved public understanding of vaccine safety. Key trends anticipated during the forecast period include the emergence of mRNA and DNA vaccine platforms, advancements in nanoparticle-based delivery methods, increased use of combination vaccines, the uptake of thermostable formulations, and innovations in needle-free delivery systems.

The growing prevalence of infectious diseases is anticipated to drive the expansion of the vaccine technologies market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can be transmitted from one individual to another. The rise in these diseases is largely attributed to increased global travel, which accelerates the spread of pathogens across borders. Vaccine technologies help in combating infectious diseases by eliciting targeted immune responses that prevent and control infections. These technologies contribute to public health by reducing the spread and severity of diseases, thereby improving overall healthcare outcomes. For example, in February 2024, the UK Health Security Agency reported that tuberculosis cases in England rose to 4,850 in 2023, marking a 10.7% increase from 4,380 cases in 2022. This surge in infectious diseases is a key factor propelling the growth of the vaccine technologies market.

Leading companies in the vaccine technologies sector are prioritizing the development of advanced solutions such as quadrivalent influenza vaccines to enhance immunization coverage and reduce the risk of strain mismatch. These vaccines are designed to protect against four influenza virus strains - two influenza A and two influenza B - offering broader protection than traditional trivalent vaccines. For instance, in February 2025, Zydus Lifesciences, an India-based pharmaceutical firm, introduced VaxiFlu-4, a quadrivalent influenza vaccine. This vaccine provides seasonal protection against four strains of influenza, including both types A and B. It is administered as a single-dose intramuscular injection and is suitable for both adults and children, helping to lessen the impact of seasonal influenza by offering more comprehensive strain coverage.

In December 2023, AstraZeneca plc, a UK-based biopharmaceutical company, acquired Icosavax Inc. for $1.1 billion. This acquisition was aimed at strengthening AstraZeneca’s respiratory vaccine portfolio through the addition of Icosavax’s innovative protein virus-like particle (VLP) platform. This platform includes a phase III-ready combination vaccine candidate, IVX-A12, which targets both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Icosavax is a US-based biotechnology company that focuses on the development of VLP-based vaccines for respiratory illnesses.

Major players in the vaccine technologies market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Moderna Inc., CSL Limited, Bharat Biotech International Limited, Bavarian Nordic A/S, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Valneva SE, Novavax Inc., Dynavax Technologies Corporation, CureVac N.V., Inovio Pharmaceuticals Inc, and Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the vaccine technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vaccine technologies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vaccine technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Vaccine technologies encompass the scientific techniques and tools utilized to create, manufacture, and administer vaccines that activate the immune system to identify and combat pathogens such as viruses, bacteria, or other harmful microorganisms. The primary goal of these technologies is to safely trigger immunity, thereby preventing diseases and helping to control the spread of infections.

There are several key types of vaccine technologies, including recombinant, conjugate, subunit, inactivated, live attenuated, and toxoid vaccines. These vaccines work by using specific components of a virus or bacterium - such as proteins or sugars - instead of the entire pathogen to safely elicit an immune response. Vaccines are delivered through various routes like parenteral, oral, and nasal methods, and are used for both infectious and non-infectious disease applications. They are suitable for all age groups, from children to adults, and are distributed through multiple channels including hospitals, retail pharmacies, government programs, and other providers.

The vaccine technologies market research report is one of a series of new reports that provides vaccine technologies market statistics, including vaccine technologies industry global market size, regional shares, competitors with a vaccine technologies market share, detailed vaccine technologies market segments, market trends and opportunities, and any further data you may need to thrive in the vaccine technologies industry. This vaccine technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vaccine technologies market consists of revenues earned by entities by providing services such as vaccine research and development, formulation and testing, clinical trials management, regulatory support, manufacturing process optimization, and distribution logistics for vaccines. The market value includes the value of related goods sold by the service provider or included within the service offering. The vaccine technologies market also includes sales of mRNA vaccines, viral vector vaccines, protein subunit vaccines, and related raw materials and reagents used in vaccine development and production. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.